Skip to content

Relapse Prevention Group Programme for service users with an international statistical classification of diseases and related health problems (ICD10, chapter F20) diagnosis of schizophrenia in a community setting - a randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN11138647
Enrollment
96
Registered
2006-07-27
Start date
2006-09-11
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia Mental and Behavioural Disorders Schizophrenia

Interventions

Relapse prevention programme as opposed to treatment as usual

Sponsors

Brent Mental Health Service (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed by a Community Psychiatric Nurse (CPN) 2. Age group 18-45, men and women 3. Have a diagnosis of schizophrenia (ICD 10-F20) 4. Sufficiently stable to take part in the programme 5. Assessment conducted by CPN 6. Living in the community 7. Be able to consent to participate 8. Be on a therapeutic dose of anti-psychotic medication

Exclusion criteria

Exclusion criteria: 1. Patients who do not speak English or cannot use an interpreter because this will be another confounder to the study 2. Patients with drug dependency as indicated by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)although alcohol/drug abusers will still be eligible for the study. The DSM- IV criterion for abuse is very restrictive and would capture most alcohol/drug use by mental health service users. The CPN?s will be provided with this to make this assessment 3. Organic brain diseases (e.g. dementia) as assessed by the psychiatrist. The psychiatrist will be asked to assess whether the patient is capable of giving informed consent and understanding what they have been asked to do 4. Patients who have previously been treated with RP 5. Patients who refuse to provide consent

Design outcomes

Primary

MeasureTime frame
1. Increased self-efficacy 2. Greater knowledge in medication, support services and illnesses 3. Improved quality of life 4. Reduced severity of symptomatology

Secondary

MeasureTime frame
1. Decrease in admission rates 2. Decrease in length of stay following admission 3. Increase in the attendance rates of hospital appointments

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026